MedPath

Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapy

Not Applicable
Recruiting
Conditions
chronic hepatitis C
Registration Number
JPRN-UMIN000016639
Lead Sponsor
Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

contraindication of Peg-IFN/Ribavirin/Vaniprevir therapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath